Krishna C. Bulusu

Affiliations: 
Cancer Therapeutics The Institute of Cancer Research 
Google:
"Krishna Bulusu"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Xu C, Us I, Cohen-Setton J, et al. (2024) PAIRWISE: Deep Learning-based Prediction of Effective Personalized Drug Combinations in Cancer. Biorxiv : the Preprint Server For Biology
Papp O, Jordán V, Hetey S, et al. (2024) Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors. Npj Systems Biology and Applications. 10: 68
Bashi AC, Coker EA, Bulusu KC, et al. (2024) Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations. Cancer Discovery. OF1-OF20
Menden MP, Wang D, Mason MJ, et al. (2019) Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nature Communications. 10: 2674
Preuer K, Lewis RPI, Hochreiter S, et al. (2017) DeepSynergy: Predicting anti-cancer drug synergy with Deep Learning. Bioinformatics (Oxford, England)
Mervin LH, Bulusu KC, Kalash L, et al. (2017) Orthologue chemical space and its influence on target prediction. Bioinformatics (Oxford, England)
Módos D, Bulusu KC, Fazekas D, et al. (2017) Neighbours of cancer-related proteins have key influence on pathogenesis and could increase the drug target space for anticancer therapies. Npj Systems Biology and Applications. 3: 2
Sebastian A, Pandey V, Mohan CD, et al. (2016) Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer. Acs Omega. 1: 1412-1424
Fechner U, de Graaf C, Torda AE, et al. (2016) 11th German Conference on Chemoinformatics (GCC 2015) : Fulda, Germany. 8-10 November 2015. Journal of Cheminformatics. 8: 18
Ain QU, Owen RM, Omoto K, et al. (2016) ANALYSIS OF DIFFERENTIAL EFFICACY AND AFFINITY OF GABAA (α1/α2) SELECTIVE MODULATORS. Molecular Pharmaceutics
See more...